<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Proc Natl Acad Sci U S A</journal-id>
<journal-id journal-id-type="iso-abbrev">Proc. Natl. Acad. Sci. U.S.A</journal-id>
<journal-id journal-id-type="hwp">pnas</journal-id>
<journal-id journal-id-type="pmc">pnas</journal-id>
<journal-id journal-id-type="publisher-id">PNAS</journal-id>
<journal-title-group>
<journal-title>Proceedings of the National Academy of Sciences of the United States of America</journal-title>
</journal-title-group>
<issn pub-type="ppub">0027-8424</issn>
<issn pub-type="epub">1091-6490</issn>
<publisher>
<publisher-name>National Academy of Sciences</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29282321</article-id>
<article-id pub-id-type="pmc">5789928</article-id>
<article-id pub-id-type="publisher-id">201715124</article-id>
<article-id pub-id-type="doi">10.1073/pnas.1715124115</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>PNAS Plus</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Biological Sciences</subject>
<subj-group>
<subject>Genetics</subject>
</subj-group>
</subj-group>
<series-title>PNAS Plus</series-title>
</article-categories>
<title-group>
<article-title>A mixed modality approach towards Xi reactivation for Rett syndrome and other X-linked disorders</article-title>
<alt-title alt-title-type="short">Combinatorial pharmacology to treat Rett syndrome</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Carrette</surname>
<given-names>Lieselot L. G.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref>
<xref ref-type="aff" rid="aff4">
<sup>d</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Chen-Yu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wei</surname>
<given-names>Chunyao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Press</surname>
<given-names>William</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ma</surname>
<given-names>Weiyuan</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>e</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>f</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kelleher</surname>
<given-names>Raymond J.</given-names>
<suffix>III</suffix>
</name>
<xref ref-type="aff" rid="aff5">
<sup>e</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>f</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lee</surname>
<given-names>Jeannie T.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref>
<xref ref-type="corresp" rid="cor1">
<sup>1</sup>
</xref>
</contrib>
<aff id="aff1"><sup>a</sup><institution>Howard Hughes Medical Institute</institution>, <institution>Massachusetts General Hospital</institution>, Boston, <addr-line>MA</addr-line> 02114;</aff>
<aff id="aff2"><sup>b</sup>Department of Molecular Biology, <institution>Massachusetts General Hospital</institution>, Boston, <addr-line>MA</addr-line> 02114;</aff>
<aff id="aff3"><sup>c</sup>Department of Genetics, <institution>Harvard Medical School</institution>, Boston, <addr-line>MA</addr-line> 02115;</aff>
<aff id="aff4"><sup>d</sup>Center for Medical Genetics, <institution>Ghent University</institution>, 9000 Ghent, <country>Belgium</country>;</aff>
<aff id="aff5"><sup>e</sup>Center for Genomic Medicine, <institution>Massachusetts General Hospital</institution>, Boston, <addr-line>MA</addr-line> 02114;</aff>
<aff id="aff6"><sup>f</sup>Department of Neurology, <institution>Massachusetts General Hospital</institution>, Boston, <addr-line>MA</addr-line> 02114</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><sup>1</sup>To whom correspondence should be addressed. Email: <email>lee@molbio.mgh.harvard.edu</email>.</corresp>
<fn fn-type="edited-by">
<p>Contributed by Jeannie T. Lee, December 1, 2017 (sent for review August 28, 2017; reviewed by Ingolf Bach and Gyorgyi Csankovszki)</p>
</fn>
<fn fn-type="con">
<p>Author contributions: L.L.G.C. and J.T.L. designed research; L.L.G.C. performed research; W.P., W.M., and R.J.K. contributed new mouse lines/analytic tools; L.L.G.C. and J.T.L. analyzed data; C.-Y. W. and C.W. performed bioinformatic analysis; and L.L.G.C. and J.T.L. wrote the paper.</p>
</fn>
<fn fn-type="con">
<p>Reviewers: I.B., UMass Medical School; and G.C., University of Michigan.</p>
</fn>
<fn fn-type="COI-statement">
<p>Conflict of interest statement: J.T.L. is a founder and scientific advisory board member of Translate Bio and Fulcrum Therapeutics. Patents have also been filed on the subject matter.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<day>23</day>
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>27</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>115</volume>
<issue>4</issue>
<fpage>E668</fpage>
<lpage>E675</lpage>
<permissions>
<copyright-year>2018</copyright-year>
<license>
<ali:license_ref specific-use="vor" xmlns:ali="http://www.niso.org/schemas/ali/1.0/"></ali:license_ref>
<license-p>Published under the <ext-link ext-link-type="uri" xlink:href="http://www.pnas.org/site/aboutpnas/licenses.xhtml">PNAS license</ext-link>.</license-p>
</license>
</permissions>
<self-uri xlink:href="pnas.201715124.pdf" xlink:title="pdf"></self-uri>
<abstract abstract-type="executive-summary">
<title>Significance</title>
<p>The X-chromosome harbors hundreds of disease genes, a subset of which gives rise to neurodevelopmental disorders such as Rett syndrome (RTT), fragile X syndrome, and CDKL5 syndrome. There is presently no disease-specific treatment. Here, we work toward a therapeutic program based on reactivation of the silent X chromosome to restore expression of the missing protein. We develop a mixed modality approach that combines a small-molecule inhibitor of DNA methylation and an antisense oligonucleotide against Xist RNA. This combination achieves up to 30,000-fold methyl-CpG binding protein 2 upregulation in cultured cells. In vivo modeling using a conditional <italic>Xist</italic> knockout and 5-aza-2′-deoxycytidine recapitulates inactive X reactivation. These findings provide proof of concept for the mixed modality approach to treat X-linked disorders, including RTT.</p>
</abstract>
<abstract>
<p>The X-chromosome harbors hundreds of disease genes whose associated diseases predominantly affect males. However, a subset, including neurodevelopmental disorders, Rett syndrome (RTT), fragile X syndrome, and CDKL5 syndrome, also affects females. These disorders lack disease-specific treatment. Because female cells carry two X chromosomes, an emerging treatment strategy has been to reawaken the healthy allele on the inactive X (Xi). Here, we focus on methyl-CpG binding protein 2 (MECP2) restoration for RTT and combinatorially target factors in the interactome of Xist, the noncoding RNA responsible for X inactivation. We identify a mixed modality approach combining an Xist antisense oligonucleotide and a small-molecule inhibitor of DNA methylation, which, together, achieve 30,000-fold MECP2 up-regulation from the Xi in cultured cells. Combining a brain-specific genetic <italic>Xist</italic> ablation with short-term 5-aza-2′-deoxycytidine (Aza) treatment models the synergy in vivo without evident toxicity. The Xi is selectively reactivated. These experiments provide proof of concept for a mixed modality approach for treating X-linked disorders in females.</p>
</abstract>
<kwd-group>
<kwd>X reactivation</kwd>
<kwd>antisense oligonucleotides</kwd>
<kwd>LNA</kwd>
<kwd>Rett syndrome</kwd>
<kwd>Xist</kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
<funding-source id="sp1">HHS | National Institutes of Health (NIH)<named-content content-type="funder-id">100000002</named-content></funding-source>
<award-id rid="sp1">R01-DA36895</award-id>
</award-group>
<award-group id="gs2">
<funding-source id="sp2">Howard Hughes Medical Institute (HHMI)<named-content content-type="funder-id">100000011</named-content></funding-source>
<award-id rid="sp2">NA</award-id>
</award-group>
<award-group id="gs3">
<funding-source id="sp3">Rett Syndrome Research Trust</funding-source>
<award-id rid="sp3">NA</award-id>
</award-group>
<award-group id="gs4">
<funding-source id="sp4">Simon Research Foundation</funding-source>
<award-id rid="sp4">NA</award-id>
</award-group>
<award-group id="gs5">
<funding-source id="sp5">FWO - Belgium</funding-source>
<award-id rid="sp5">NA</award-id>
</award-group>
<award-group id="gs6">
<funding-source id="sp6">BAEF (Belgium)</funding-source>
<award-id rid="sp6">NA</award-id>
</award-group>
</funding-group>
<counts>
<page-count count="8"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>